Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials

BACKGROUND AND OBJECTIVE: Hydrocodone bitartrate extended release (Hysingla(®) ER, HYD) was previously studied in a 12-week randomized, double-blind, placebo-controlled trial and a 52-week open-label safety study. Both of these preapproval studies allowed dose titration to efficacy. The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Taber, Louise, Bond, T Christopher, Wang, Xuezhe, Kadakia, Aditi, Mayne, Tracy J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536138/
https://www.ncbi.nlm.nih.gov/pubmed/28794653
http://dx.doi.org/10.2147/JPR.S140990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536138/
https://www.ncbi.nlm.nih.gov/pubmed/28794653
http://dx.doi.org/10.2147/JPR.S140990

Ejemplares similares